Chordate Medical Holding AB (OSTO:CMH) Net-Net Working Capital: kr0.41 (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CMH Chordate Medical Holding AB OSTO:CMH
46 GF Score
Price kr0.16
View Full Analysis

What is Chordate Medical Holding AB Net-Net Working Capital?

Chordate Medical Holding AB OSTO:CMH -60.40% 46 Net-Net Working Capital is kr0.41 as of Jun. 2025. GuruFocus rates OSTO:CMH with a GF Score™ of 46/100.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Chordate Medical Holding AB's Net-Net Working Capital for the quarter that ended in Jun. 2025 was kr0.41.

The industry rank for Chordate Medical Holding AB's Net-Net Working Capital or its related term are showing as below:

OSTO:CMH's Price-to-Net-Net-Working-Capital is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 6.85
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Chordate Medical Holding AB  (OSTO:CMH) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Chordate Medical Holding AB Net-Net Working Capital Related Terms


Chordate Medical Holding AB Net-Net Working Capital Historical Data

* Premium members only.

The historical data trend for Chordate Medical Holding AB's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordate Medical Holding AB Net-Net Working Capital Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.16 -6.47 4.09 -4.06

Chordate Medical Holding AB Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.62 2.04 -4.06 2.83 0.41

OSTO:CMH vs ABT, SYK, MDT: Net-Net Working Capital Comparison

For the Medical Devices subindustry, Chordate Medical Holding AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB Price-to-Net-Net-Working-Capital vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's Price-to-Net-Net-Working-Capital falls into.


OSTO:CMH
46GF Score
Chordate Medical Holding AB OSTO:CMH
Net-Net Working Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordate Medical Holding AB Net-Net Working Capital Calculation

Chordate Medical Holding AB's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net-Net Working Capital(A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(2.53+0.75 * 0.253+0.5 * 1.765-8.335
-0-0)/1.165
=-4.06

Chordate Medical Holding AB's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2025 is calculated as

Net-Net Working Capital(Q: Jun. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(4.244+0.75 * 0.155+0.5 * 1.793-4.143
-0-0)/2.700
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

What does a Net-Net Working Capital of kr0.41 mean?
Chordate Medical Holding AB (OSTO:CMH) has a Net-Net Working Capital of kr0.41 as of Jun. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Chordate Medical Holding AB
Is Chordate Medical Holding AB's Net-Net Working Capital too high?
Chordate Medical Holding AB's current Net-Net Working Capital is kr0.41. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's Net-Net Working Capital compare to ABT and SYK?
Chordate Medical Holding AB's Net-Net Working Capital of kr0.41 can be compared against companies in the Medical Devices & Instruments industry. The industry median Net-Net Working Capital is 6.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Devices & Instruments company?
The median Net-Net Working Capital among Medical Devices & Instruments companies is 6.85, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Chordate Medical Holding AB For the Medical Devices & Instruments industry, the median Net-Net Working Capital is 6.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chordate Medical Holding AB's current Net-Net Working Capital is kr0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current Net-Net Working Capital of kr0.41. The current Net-Net Working Capital is kr0.41. Chordate Medical Holding AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current Net-Net Working Capital is kr0.41 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordate Medical Holding AB Business Description

Address Farogatan 33, 164 51 Kista, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score

Get the complete analysis for OSTO:CMH

Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.16
Price